@sigtrans-sttt.bsky.socialAdvanced #SCLC requires innovative therapeutic strategies beyond standard #Chemoradiotherapy.
A randomized trial reports improved progression-free and overall survival with camrelizumab-based induction and consolidation therapy.
@btog.bsky.socialWhere does thoracic radiotherapy fit in extensive-stage #SCLC in the immunotherapy era?
Dr Huiqi Yang: consolidation RT should be offered to good responders after chemotherapy, but its role following chemoimmunotherapy remains uncertain.
#BTOGSCLC26 #LCSM
@btog.bsky.socialCould radiopharmaceuticals become another way to target #SCLC?
Dr Toby Talbot explains how a radioisotope can be delivered to tumour-specific targets – a similar principle to an ADC, but with radiation replacing the drug payload.
#BTOGSCLC26 #LCSM
@btog.bsky.socialIf SCLC is changing, and brain-directed radiotherapy is changing, then brain-directed RT in SCLC is also changing.
Waleed Mohammed tackles one of today’s controversies: the evolving role of PCI, MRI surveillance and SRS/SRT.
@btog.bsky.socialEarly treatment impacts survival in extensive-stage #SCLC.
Prof Samreen Ahmed highlights the rapid attrition after first-line therapy – real-world data suggest only 21.9% of patients transition to second-line treatment.
Her message: keep the threshold for treatment low.
#BTOGSCLC26 #LCSM
@btog.bsky.social“Large volumes can still be curatively treated.”
Hannah Bainbridge discusses optimising thoracic radiotherapy in limited-stage #SCLC – from staging and patient fitness to planning, dose, motion management and adaptive treatment.
#BTOGSCLC26 #LCSM
@btog.bsky.socialSpeed matters in #SCLC.
Emma Halkyard shares Greater Manchester’s work to accelerate the diagnostic pathway: if SCLC is suspected, alert everyone involved in the pathway as early as possible.
A system-wide, multi-professional approach is key.
#BTOGSCLC26 #LCSM
@jckaelin.bsky.socialWe need leaders like this, now!!! #KeepHopeAlive!!!
#OTD #TDIH #October8, 1941: #HBD #JesseJackson! #CivilRightsActivists #Ministers #CivilRightsMovement #RainbowCoalition #SCLC #Democrats #DemocraticPartyPresidentialNominee #SelmaToMontgomeryMarches #Nonviolence #AntiRacism #DemocraticSky
@jckaelin.bsky.social@jckaelin.bsky.social
@tamedoncol.bsky.socialGet ready for #ESMO26 by revisiting the evolving treatment landscape of #SCLC with this review published on #TAMO in 2025.
From current standards to DLL3-targeted therapies, #ADCs and emerging biomarkers.
#Lungcancer
🔗 buff.ly/B2U9VpQ
@Roya_Behrouzi @fblackhall
@oncoalert.bsky.social🧬 Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy?
SKYSCRAPER-02C🫁 Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage #SCLC
@onc-rg.bsky.social𝙏𝙝𝙚 2026 𝙀𝙎𝙈𝙊 𝙇𝘽𝘼 𝙇𝙖𝙣𝙙𝙨𝙘𝙖𝙥𝙚: 𝙑𝙞𝙨𝙪𝙖𝙡𝙞𝙯𝙚𝙙.
Which mechanisms are commanding the late-breaker spotlight this year?
#ESMO2026 #ESMO26 #Oncology #NSCLC #SCLC #ADCs #vaccines #ClinicalData #DrugTrials #CompetitiveStrategy
@medthority.bsky.socialWhat were the biggest #SCLC highlights from #WCLC2026? Watch Giannis Mountzios share his perspective on the MAVERICK trial, novel antibody-drug conjugates, and evolving treatment strategies that are reshaping the care landscape
@healthcare-europe.bsky.socialAfter treatment for #SCLC #lungcancer, patients often undergo prophylactic #radiotherapy to prevent #metastases in the brain. Now, a new study presented by Chad Rusthoven, MD, from 🇺🇸 @cumedicalschool.bsky.social at @iaslc.bsky.social's #WCLC26, shows that #MRI surveillance alone is enough.
@springermedicine.com#MedNews - Treatment with the novel antibody–drug conjugate tambotatug pelitecan significantly prolongs the survival of patients with small-cell lung cancer that has progressed after first-line therapy.
@saccultural.bsky.socialSign languages are complete, natural languages with their own grammar, history, and cultural identity. Recognizing them advances accessibility, inclusion, and human dignity.
#SignLanguagesDay #LanguageAccess #SCLC
@precogonc.bsky.socialShout out to @OSUCCC_James & for enrolling its first patient in PrE0510, our phase 2 #ClinicalTrial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage #SmallCellLungCancer (#SCLC). Learn more: bit.ly/PrE0510
@ukmarkey.bsky.socialUK Markey Cancer Center is the 1st U.S. site to initiate a trial for ZG006 (Alveltamig) in relapsed #SCLC. Its 3-arm design (2 tumor + 1 T-cell) aims for stronger binding than bispecifics.
Details for referring oncologists & researchers: https://bit.ly/3YKfoV8
@onc-rg.bsky.social